Neogen (NEOG) Liabilities from Discontinued Operations (2025 - 2026)
Neogen's quarterly Liabilities from Discontinued Operations came in at 6400000.0 in Q1 2026, down 29.72% quarter-over-quarter from 9107000.0 in Q4 2025.
Neogen has reported Liabilities from Discontinued Operations for 2 years, with the latest figure at 6400000.0 in Q1 2026.
- For the quarter ending Q1 2026, Liabilities from Discontinued Operations changed N/A year-over-year to 6400000.0; the trailing twelve-month figure through Feb 2026 stood at 6400000.0 (changed N/A YoY), and the FY2025 full-year result was 6600000.0, changed N/A from the prior year.
- Liabilities from Discontinued Operations for Q1 2026 stood at 6400000.0, down from 9107000.0 in the prior quarter.
- The five-year high for Liabilities from Discontinued Operations was 9107000.0 in Q4 2025, with the low at 6400000.0 in Q1 2026.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn |
| 10 | Neogen | 1.94 Bn | 1.78 Bn | 99.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Feb 28, 2026 | 6.40 Mn |
| Feb 28, 2026 | 6.40 Mn |
| Nov 30, 2025 | 9.11 Mn |
| Nov 30, 2025 | 9.11 Mn |
| May 31, 2025 | 6.60 Mn |
| May 31, 2025 | 6.60 Mn |